Lilly shares safety, tolerability data on its next-gen obesity drug
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Revolution Medicines’ pancreatic cancer drug proving hard to get
Amy Johnston is distraught and readily admits that she is “grasping at straws.” Diagnosed last year with pancreatic…
New hormone protocol cut relapse risk in prostate cancer trial
Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of…
Revolution Medicines starts early access for pancreatic cancer drug
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
White House gutted pandemic preparation plans. Then came Ebola
Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in…
NIH grants: Trump administration moves to solidify political control
The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants, and…
Eli Lilly: Single-shot gene therapy lowered cholesterol in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in…
Acting head of NIH’s infectious disease institute reported to have stepped down
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her…
FDA leadership void grows: Tracy Beth Høeg out as CDER chief
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Betrayed by RFK Jr., targeted by Trump, Bill Cassidy faces voters
BATON ROUGE, La. — When it comes to Bill Cassidy, most everyone in Louisiana politics — supporters and…
Intellia Therapeutics moves HAE treatment closer to approval
Intellia Therapeutics said Monday that a single dose of its gene editing treatment dramatically reduced swelling attacks in…
Erasca touts strong early results in pancreatic and lung cancer therapy trial
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…